Table 1.
Characteristics of the study population (n = 1244)
| Parameter | Category/statistic | |
|---|---|---|
| Male/female | n/n | 787/457 |
| Age (years) | Mean (SD) | 63.3 (11.28) |
| Median (Q1–Q3) | 64.0 (58.0–71.0) | |
| Range | 18–92 | |
| Body weight (kg) | Mean (SD) | 84.5 (16.59) |
| Median (Q1–Q3) | 83.0 (73.5–94.0) | |
| Range | 42–173 | |
| Time since diagnosisa | < 1 year | 220 (17.7%) |
| ≥ 1 and < 2 years | 81 (6.5%) | |
| ≥ 2 and < 5 years | 131 (10.5%) | |
| ≥ 5 years | 534 (42.9%) | |
| Unknown | 278 (22.3%) | |
| Subgroup | FH | 307 (24.7%) |
| Secondary prevention | 943 (75.8%) | |
| Diabetes | 528 (42.4%) | |
| STEMI | 208 (16.7%) | |
| Statin intolerantb | 127 (10.2%) | |
| DLCN score (FH patients) | < 3 | 51 (16.3%) |
| 3–5 | 86 (27.5%) | |
| 6–7 | 86 (27.5%) | |
| ≥ 8 | 84 (26.8%) | |
| CV risk | High | 151 (12.1%) |
| Very high | 1093 (87.9%) |
DLCN Dutch Lipid Clinic Network criteria [12]: definite/probable FH ≥ 6; possible FH 3–5; unlikely FH < 3; FH Familial hypercholesterolaemia; STEMI ST-Elevation Myocardial Infarction
aDiagnosis of hyperlipidaemia
bPatients with adverse events attributed to statin intolerance